All News
Save the date! It is a pleasure to announce the 4th Digital Rheumatology Day which will take place in Berlin on May 6. Program will be out soon: https://t.co/CFZBsE7gbn https://t.co/K3tKiniys9
Digital Rheumatology Network digital_rheuma ( View Tweet)
Congrats Art!!! https://t.co/g7PQ1gs7Er
Dr. John Cush RheumNow ( View Tweet)
Blurred line indeed, one could argue that a patient with ACPA+, arthralgia and sub-clinical inflammation detected on MRI is already transitioning toward early RA and fall into the category of patients we should treat anyway. https://t.co/Y1JceOijK0
Aurelie Najm AurelieRheumo ( View Tweet)
If you've heard about Build Back Better in the news, and want to know if affects Rheumatology 👇
Thanks @ACRheumDC and #rheumpac for your help.
Looking forward to #ACR21 advocacy session Sunday at 11am! @zach_wallace_md @BlairSolowMD https://t.co/mDCzg0fXcU
Eric Dein ericdeinmd ( View Tweet)
#ACR21 is just days away and we want to see your best images of learning virtually, missing a meeting in San Francisco, wellness, or break time activities.
Tweet your pic and make sure to include #RheumPix and #ACR21 and we’ll share our favorites. https://t.co/UwaO9c6ODW
Dr. John Cush RheumNow ( View Tweet)
Thank you ACR Convergence Today for the interview and featuring my abstract ! #ACR21 @ACRheum
https://t.co/JISSTSDt1d https://t.co/roh5BSgbeD
Links:
Akhil Sood MD AkhilSoodMD ( View Tweet)
‘Activity based programs including physical activity and mindful based exercises can help to reduce pain. These are strategies to assist while managing from pharmacological standpoint.’ @UnaMakris
Akhil Sood MD AkhilSoodMD ( View Tweet)
‘We need to identify patients at increased risk for cognitive impairment.’ @MyasoedovaElena
Akhil Sood MD AkhilSoodMD ( View Tweet)
@KDAO2011 @Yuz6Yusof @drdavidliew @Janetbirdope @uptoTate @ericdeinmd @doctorRBC @synovialjoints @MeralElRamahiMD @DrMiniDey @_Castillo_Pedro @DrPetryna @AkhilSoodMD @swethaann23 @RHEUMarampa @RichardPAConway
Follow us!
Aurelie Najm AurelieRheumo ( View Tweet)
Also, yes I was sporting a beard for the recording #ACR21🧔 https://t.co/EK7N9X7zL7
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
Kudos to this year’s recipients of the Distinguished Fellow Award! Distinguished Fellows → https://t.co/rS4IELAmd1 #ACR21 https://t.co/855fjYbPao
Links:
American College of Rheumatology ACRheum ( View Tweet)
@rheum_cat @KDAO2011 @RheumEpi @JYazdanyMD @RADoctor That too... so many great moments in this video... also this reaction --> 😕
😂😂😂 @alhkim https://t.co/kAYBgPk1aB
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
When you sign up to bike the ACR Virtual 5k, but it’s 62 degrees and beautiful in MN in November, you keep going and make it 20k.#acr21 #RheumPix https://t.co/j1Smoga41r
Julie Jones 🏳️🌈🐈⬛🐈 JonesN4Rheum ( View Tweet)
and for those interested in the detail:
- remnant TAB divided and culture ex vivo with placebo, mavrilimumab, tocilizumab
- inflamm transcriptomics panel
- 81 differentially expressed genes assessed
- categorised by function https://t.co/0MWZk82Gj5
David Liew drdavidliew ( View Tweet)
Great start to #ACR21 and great recap of the year in rheumatology.
Positive data on tofacitinib and AS but still pending approval.
Where would JAKinibs be in your AS treatment algorithm?🤔
@RheumNow https://t.co/cs8U33355A
Robert B Chao, MD doctorRBC ( View Tweet)
#ACR21 Abst#0910 by @rheum_cat. Do TNFi ⬆️ risk of incident HTN in AxSpa?
⭐️PSOAS cohort: Prosp study from 2003-2018
▶️When adjusted for confounders (obesity, disease activity, NSAID use), insufficient evidence to show ⬆️ risk of HTN w TNFi
https://t.co/DCZ3W8CkOa @Rheumnow
Links:
Eric Dein ericdeinmd ( View Tweet)
Exciting day at #ACR21
I wrote an article discussing COVID 19 in #RheumatoidArthritis discussing the following abstracts
0097 by Hasseli
1445 by @NamrataRheum
L04 by @rheum_cat & @rheum_covid
@rheumnow #COVID19 #RA #JAK #Rituximab
https://t.co/g32ZYHBjQY
Akhil Sood MD AkhilSoodMD ( View Tweet)
#ACR21 Abst#0916. https://t.co/uc5JDVY0ud
Your patient has had 1 yr of remission of AxSpa on Certolizumab pegol, tolerating the medication. What do you recommend @Rheumnow
Links:
Eric Dein ericdeinmd ( View Tweet)
Dr. Thaissa Cotton on SLE + ILD and/or myositis: important given poorer outcomes. Ask pts and listen to those lungs!
💠1.8 cases/100 patient years (14/551 pts in study)
💠92.9% had >=1 med-to-high titer marker
💠⬆️risk if baseline +anti KL-6, Ku, CENPB
#ACR21 Abst#0330 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
#ACR21 Abst#0916
⭐️AxSpa pts in remission: Full Certolizumab vs 1/2 dose vs PBO
▶️ 85% w/o flare in full dose, 80% in 1/2 dose, just 23% in PBO
▶️ PBO pts with NO flare STILL showed ⬆️ ASDAS, BASDAI, and CRP
🔥Would ⬇️ not d/c Cimzia!
@Rheumnow https://t.co/uc5JDVY0ud #ACRBest https://t.co/fOssPlTEwR
Links:
Eric Dein ericdeinmd ( View Tweet)